Enlivex Therapeutics Ltd Stock

$1.20

0.83% yesterday

Nasdaq, Jun 27, 10:12 pm CET

ISIN

IL0011319527

Symbol

ENLV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Enlivex Therapeutics Ltd Stock price

$1.20

-4.87 80.21% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.01 0.83%

ISIN

IL0011319527

Symbol

ENLV

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$28.6m

Enterprise Value

$8.1m

Net debt

$-20.6m

Cash

$20.6m

Shares outstanding

23.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

1.39

Financial Health

Equity Ratio

85.20%

Return on Equity

-63.65%

ROCE

-72.20%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-14.6m | -

EBIT

$-15.1m

Net Income

$-14.3m | $-14.2m

Free Cash Flow

$-13.2m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

31.94% | -

EBIT

32.39%

Net Income

44.86% | 5.20%

Free Cash Flow

40.95%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-0.60

FCF per Share

$-0.55

Short interest

0.33%

Employees

71.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Enlivex Therapeutics Ltd Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Enlivex Therapeutics Ltd forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Enlivex Therapeutics Ltd forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Enlivex Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	4.77 4.77	15% 15% -
- Research and Development Expense	10 10	38% 38% -
EBITDA	-15 -15	32% 32% -
- Depreciation and Amortization	0.45 0.45	44% 44% -
EBIT (Operating Income) EBIT	-15 -15	32% 32% -
Net Profit	-14 -14	45% 45% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Enlivex Therapeutics Ltd Stock News

Neutral

GlobeNewsWire

●

18 days ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a poster at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, taking place June 11-14, 2025, in Barcelona, Spain.

Neutral

GlobeNewsWire

●

about one month ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company has been selected to present at the upcoming Israeli BioMed 2025 Conf...

Neutral

GlobeNewsWire

●

2 months ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Presentations to underscore AllocetraTM's novel mechanism targeting immune imbalance in joint disease Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI)...

More Enlivex Therapeutics Ltd News

Company Profile

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Head office	Israel
CEO	Dr. Hershkovitz
Employees	71
Founded	2012
Website	www.enlivex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now